HALO
Halozyme Therapeutics, Inc.
$77.54
+1.72 (+2.27%)
At close · Jul 16
Market Cap
$9.20B
Shares
118,613,000
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.4B
+37.6%
FY2025
Net Income
$316.89M
-28.6%
FY2025
Gross Margin
83.62%
-0.7pp
FY2025
Operating Margin
33.58%
-20.7pp
FY2025
Diluted EPS
$2.56
-25.4%
FY2025
Operating Cash Flow
$651.56M
+36%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $1.51B | $1.4B | $1.02B | $829.25M | $660.12M | $443.31M | $267.59M | $195.99M | $151.86M | $316.61M | $146.69M | $135.06M | $75.33M | $54.8M | $42.33M | $56.09M | $13.62M | $13.67M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $59.03K | $63.53K | $49.02K | $100.75K | |
| — | $259.61M | $228.77M | $159.42M | $192.36M | $139.3M | $81.41M | $43.37M | $45.55M | $10.14M | $31.15M | $33.21M | $29.25M | $22.73M | $6.25M | $1.09M | $257.83K | $985.28K | $311.89K | |
| — | $1.25B | $1.17B | $855.91M | $636.89M | $520.81M | $361.9M | $224.23M | $150.45M | $141.73M | $285.46M | $113.49M | $105.81M | $52.6M | $48.55M | $41.23M | $55.83M | $12.64M | $13.36M | |
| — | — | 83.62% | 84.3% | 76.8% | 78.9% | 81.64% | 83.79% | 76.76% | 93.33% | 90.16% | 77.36% | 78.35% | 69.83% | 88.6% | 97.42% | 99.54% | 92.77% | 97.72% | |
| — | $92.25M | $81.49M | $79.05M | $76.36M | $66.61M | $35.67M | $34.24M | $140.8M | $150.25M | $150.64M | $150.84M | $93.24M | $79.7M | $96.64M | $70.04M | $57.56M | $51.77M | $56.61M | |
| — | $222.61M | $207.09M | $154.34M | $149.18M | $143.53M | $50.32M | $45.74M | $77.25M | $60.8M | $53.82M | $45.85M | $40.03M | $35.94M | $32.35M | $24.81M | $18.1M | $15.12M | $15.2M | |
| — | $88.41M | $76.66M | $71.05M | $73.77M | $43.15M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| — | $12.92M | $11.39M | $10.26M | $11.08M | $6.49M | $3M | $3.28M | $4.07M | $2.39M | $2.16M | $2.41M | $1.68M | $1.76M | $1.23M | $1.08M | $1.1M | $1.51M | $1.44M | |
| — | $996.47M | $927.61M | $463.85M | $491.68M | $392.59M | $167.41M | $123.34M | $263.6M | $221.19M | $235.61M | $229.9M | $162.51M | $138.37M | $135.23M | $95.95M | $75.93M | $67.88M | $72.13M | |
| — | $511.99M | $469.01M | $551.48M | $337.57M | $267.53M | $275.9M | $144.26M | -$67.61M | -$69.33M | $81M | -$83.21M | -$27.45M | -$63.04M | -$80.43M | -$53.63M | -$19.84M | -$54.26M | -$58.46M | |
| — | — | 33.58% | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% | -34.5% | -45.65% | 25.58% | -56.72% | -20.33% | -83.68% | -146.78% | -126.7% | -35.37% | -398.25% | -427.6% | |
| — | $524.91M | $480.4M | $561.74M | $348.66M | $274.02M | $278.9M | $147.54M | -$63.54M | -$66.94M | $83.16M | -$80.8M | -$25.78M | -$61.27M | -$79.21M | -$52.55M | -$18.74M | -$52.75M | -$57.01M | |
| — | $19.11M | $18.13M | $18.1M | $18.76M | $16.95M | $7.53M | $20.38M | $11.63M | $18.04M | $21.98M | $19.98M | $5.2M | $5.58M | $3.27M | $0 | $0 | — | — | |
| — | $15.97M | $21.47M | $23.75M | $16.32M | $1.05M | $1.1M | $5.43M | $6.99M | $7.58M | $2.59M | $1.33M | $422K | — | — | $73.44K | $69.09K | $1.02M | $97.74K | |
| — | $503.37M | $466.88M | $557.13M | $348.33M | $248.92M | $248.52M | $129.3M | -$72.25M | -$79.79M | $61.61M | -$101.86M | -$32.23M | -$68.38M | — | — | — | — | — | |
| — | $154.53M | $149.99M | $113.04M | $66.74M | $46.79M | -$154.19M | $217K | -$11K | $537K | -$1.36M | $1.16M | $0 | $0 | — | — | — | — | — | |
| — | $348.84M | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M | $129.09M | -$72.24M | -$80.33M | $62.97M | -$103.02M | -$32.23M | -$68.38M | -$83.48M | -$53.55M | -$19.77M | -$53.24M | -$58.36M | |
| — | — | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% | -36.86% | -52.9% | 19.89% | -70.23% | -23.86% | -90.76% | -152.34% | -126.53% | -35.25% | -390.79% | -426.88% | |
| — | $339.55M | $294.97M | $457.2M | $273.24M | $201.83M | $402.07M | $128.87M | -$71.72M | -$80.16M | $62.53M | -$102.93M | -$32.29M | -$68.43M | -$83.46M | -$53.55M | -$19.77M | -$53.24M | — | |
| USD/shares | — | — | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 | $0.95 | -$0.50 | -$0.56 | $0.46 | -$0.81 | -$0.25 | — | — | — | — | — | — |
| USD/shares | $7.75 – $8.25* | — | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | -$0.50 | -$0.56 | $0.45 | -$0.81 | -$0.25 | — | — | — | — | — | — |
| shares | — | — | 119.84M | 126.83M | 131.93M | 136.84M | 140.65M | 136.21M | 144.33M | 143.6M | 136.42M | 127.96M | 126.7M | 122.69M | 112.81M | 111.08M | 102.57M | — | — |
| shares | — | — | 123.9M | 129.42M | 134.2M | 140.61M | 146.8M | 141.46M | 144.33M | 143.6M | 139.07M | 127.96M | 126.7M | 122.69M | 112.81M | 111.08M | 102.57M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2025: $1.89B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
7.31×
Biotechnology median 8.53×
EV/EBIT
21.55×
Biotechnology median 26.49×
P/E (TTM)
27.21×
Biotechnology median 7.39×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Royalty | $867,840,000 | $570,991,000 | $447,865,000 | $360,475,000 | $203,900,000 | $88,596,000 | $69,899,000 | $78,981,000 |
| Product | $376,444,000 | $303,492,000 | $300,854,000 | $191,030,000 | $104,224,000 | $55,987,000 | $66,048,000 | $28,234,000 |
| Proprietary Products Sales | $194,608,000 | $166,620,000 | $130,834,000 | $72,849,000 | $23,264,000 | $17,031,000 | — | — |
| Collaborative Agreements | $152,327,000 | $140,841,000 | $80,534,000 | $108,611,000 | $135,186,000 | $123,011,000 | $60,045,000 | $44,647,000 |
| Bulk rHuPH20 | $133,023,000 | $86,334,000 | $115,442,000 | $82,084,000 | $80,960,000 | — | — | — |
| Sales-Based Milestone | $70,000,000 | $30,000,000 | $0 | $10,000,000 | $50,000,000 | $15,000,000 | $0 | $0 |
| Device Partnered Products | $48,813,000 | $50,538,000 | $54,578,000 | $36,097,000 | $0 | $0 | — | — |
| Event Based Development And Regulatory Milestone And Other Fees | $47,000,000 | $72,500,000 | $69,000,000 | $59,000,000 | $42,000,000 | — | — | — |
| Upfront Fees | $18,471,000 | $27,000,000 | $2,000,000 | $30,000,000 | — | — | — | — |
| Device Licensing and Development | $16,856,000 | $11,341,000 | $9,534,000 | $9,611,000 | — | — | — | — |
| Bulk rHuPH20 | — | — | — | $82,084,000 | $80,960,000 | $38,956,000 | $49,053,000 | $12,729,000 |
| Development Fees | — | — | — | $59,000,000 | $42,000,000 | $69,500,000 | $5,500,000 | $16,000,000 |
| ENHANZE Drug Product Member Domain | — | — | — | — | — | $719,000 | $768,000 | $460,000 |
| Hylenex Recombinant | — | — | — | — | $23,263,000 | $17,031,000 | $16,995,000 | $15,045,000 |
| Research and Development Services | — | — | $9,534,000 | $9,611,000 | $1,186,000 | $1,247,000 | $1,545,000 | $2,311,000 |
| Upfront Fees | — | — | $2,000,000 | $30,000,000 | $42,000,000 | $37,264,000 | $53,000,000 | $26,336,000 |
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
78 filings
73 filers
Visit website
Investor relations